GlassScriptPhysician profile
Lanning A Anselmi
NPI 1932112638
$11,496.56
in general payments reported to CMS, 2019-2025
50 companies · $1,669 in 2025
The $1,669 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,145 · 2020: $1,555 · 2021: $1,623 · 2022: $1,320 · 2023: $1,462 · 2024: $1,722 · 2025: $1,669.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,854.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,853.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,281.32 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,281.04 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,101.65 | 2019-2025 | Ubrelvy, Vraylar, Synthroid |
| Amgen INC. | $1,018.11 | 2019-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $911.88 | 2019-2025 | Jardiance, Tradjenta, Stiolto Respimat |
| Glaxosmithkline, LLC. | $822.17 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Pfizer INC. | $800.48 | 2019-2025 | |
| Lilly USA, LLC | $718.36 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $495.93 | 2019-2025 | Veozah |
| Avanir Pharmaceuticals, INC. | $278.41 | 2019-2021 | |
| Amarin Pharma, INC. | $251.64 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $236.57 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $225.46 | 2019-2025 | Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $212.72 | 2019-2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $191.65 | 2024-2025 | Voquezna |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lanning Anselmi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.